10-Q: TriSalus Reports Strong Revenue Growth Amidst Losses

TriSalus Life Sciences, Inc. reported significant revenue growth in Q2 2025, driven by new product launches, but continues to face substantial net losses and going concern uncertainties.

Summary

• Revenue increased by 52.3% to $11.2 million for the three months ended June 30, 2025, compared to $7.4 million in the prior year period.
• For the six months ended June 30, 2025, revenue grew 47.5% to $20.4 million, up from $13.8 million in the same period last year.
• Gross profit for the three months ended June 30, 2025, was $9.4 million (83.9% gross margin), an increase from $6.5 million (87.6% gross margin) in Q2 2024.
• Net loss available to common stockholders for Q2 2025 was $(8.3) million, compared to $(4.3) million in Q2 2024.
• For the six months ended June 30, 2025, net loss available to common stockholders was $(18.7) million, compared to $(17.5) million in H1 2024.
• Cash and cash equivalents stood at $26.5 million as of June 30, 2025, a significant increase from $8.5 million at December 31, 2024.
• Accumulated deficit reached $298.2 million as of June 30, 2025.
• Net cash used in operating activities improved to $(11.8) million for the six months ended June 30, 2025, from $(24.3) million in the prior year period.
• The company successfully completed a private placement, raising approximately $22.0 million in gross proceeds in May 2025.
• An additional $10.0 million was drawn from the OrbiMed Credit Agreement in February 2025, based on achieving a $30.0 million trailing 12-month product revenue base.
• All Series A Convertible Preferred Stock was converted into 11,813,059 common shares on July 31, 2025, following a tender offer.

Sentiment

Score: 4

Explanation: While revenue growth is strong and cash burn from operations has improved, the continued net losses, growing accumulated deficit, and explicit 'going concern' warning are significant negatives. The identified material weaknesses in internal controls further dampen sentiment. The capital raises provide temporary relief but do not resolve the fundamental profitability challenge.

Positives

• Strong revenue growth: 52.3% increase in Q2 2025 and 47.5% increase in H1 2025, driven by increased TriNav unit sales and a price increase.
• Improved cash position: Cash and cash equivalents increased to $26.5 million as of June 30, 2025, from $8.5 million at December 31, 2024.
• Reduced cash burn from operations: Net cash used in operating activities decreased to $11.8 million in H1 2025 from $24.3 million in H1 2024.
• Successful capital raise: Completed a private placement of common stock, generating $22.0 million in gross proceeds.
• Access to additional debt financing: Successfully drew an additional $10.0 million from the OrbiMed Credit Agreement.
• New product launches: Introduced TriNav LV Infusion System, TriGuide Guiding Catheter (2024), and TriNav FLX (June 2025) to expand the PEDD device portfolio.
• Expanded market opportunity: Initiated the PROTECT registry study for thyroid disease, estimating an incremental $400.0 million market opportunity (50,000 procedures).
• Reimbursement clarity: Secured a second unique and permanent HCPCS code (C8004) effective April 1, 2025, for mapping procedures prior to TARE, enhancing reimbursement clarity.
• Preferred stock conversion: Successfully converted approximately 98.8% of outstanding preferred stock into common stock, simplifying the capital structure.

Negatives

• Continued net losses: Reported a net loss of $(8.3) million in Q2 2025 and $(18.7) million in H1 2025, indicating ongoing unprofitability.
• Accumulated deficit: The accumulated deficit grew to $298.2 million as of June 30, 2025.
• Going concern doubt: Management estimates existing cash and cash equivalents are insufficient to fund projected liquidity requirements for the next 12 months, raising substantial doubt about the ability to continue as a going concern.
• Declining gross margin: Gross margin decreased to 83.9% in Q2 2025 from 87.6% in Q2 2024, primarily due to lower manufacturing efficiency associated with newly launched products and planned shutdowns.
• Increased operating expenses: Sales and marketing expenses increased by 19.3% in Q2 2025 and 9.5% in H1 2025, driven by headcount increases. General and administrative expenses increased by 43.0% in Q2 2025 and 23.8% in H1 2025 due to professional services and filing/audit expenses.
• Increased interest expense: Interest expense significantly increased by $0.5 million in Q2 2025 and $1.8 million in H1 2025 due to increased usage of the OrbiMed Credit Agreement.
• Material weaknesses in internal controls: Identified material weaknesses in internal control over financial reporting, including insufficient trained resources, inadequate controls over accounting for significant transactions, and IT security.

Risks

• Ability to raise future financing and service indebtedness, including accessing additional delayed draws.
• Changes in applicable laws or regulations, particularly regarding reimbursement rates for TriNav.
• Ability to retain or recruit key officers, employees, or directors.
• Successful commercialization of product candidates and timing/results of clinical trials and regulatory approvals for nelitolimod.
• Estimates regarding expenses, future revenue, capital requirements, and needs for additional financing.
• History of operating losses and expectations of significant expenses and continuing losses for the foreseeable future.
• Ability to execute business strategy, including growing market share and serving new markets.
• Ability to develop and maintain brand and reputation.
• Ability to partner with other companies for product development (e.g., nelitolimod).
• Ability to obtain and maintain intellectual property protection and avoid infringement on others' rights.
• Ability to manage growth effectively.
• Maintaining Nasdaq Global Market listing and potential liquidity/trading of securities.
• Outcome of any legal proceedings.
• Unfavorable conditions in the industry, global economy, or global supply chain (e.g., financial/credit market fluctuations, international trade relations, pandemics, political turmoil, natural catastrophes, warfare, terrorist attacks).
• Risk that continuing reimbursement for TriNav may not be available at similar rates or at all, following the expiration of TPT authorization.
• Risk of being forced to delay, reduce, or eliminate research and development programs or future commercialization efforts if unable to raise additional capital on attractive terms.

Future Outlook

The company anticipates continued significant expenses due to investments in R&D and sales and marketing, and expects to incur net losses for the foreseeable future. It plans to pursue a pharmaceutical partner for future clinical development of nelitolimod. The company is evaluating the impact of the recently enacted One Big Beautiful Bill Act on its financial statements. Future capital requirements will depend on factors such as TriNav commercialization success, regulatory approval for nelitolimod, and the ability to draw remaining debt facilities.

Management Comments

• Our current operating plan, which is in part determined based on our most recent results and trends, along with the items noted above, causes substantial doubt to exist about our ability to continue as a going concern and managements plans do not alleviate the existence of substantial doubt.
• Our ability to fund future operations and to continue the execution of our long-term business plan and strategy will require that we raise additional capital through a combination of collaborations, strategic alliances and licensing arrangements, and issuance of additional equity and/or debt.
• The year-over-year decline in gross margin was primarily driven by lower manufacturing efficiency associated with newly launched products, a dynamic we expect to improve as production scales and processes mature over the course of the year.
• We are a high growth, high margin company approaching a level of revenues that can generate sufficient cash flow to sustain our operations.

Industry Context

TriSalus operates in the highly competitive and rapidly evolving medical technology and pharmaceutical markets, specifically targeting solid tumors with its PEDD infusion systems and investigational immunotherapeutic, nelitolimod. The company's focus on overcoming intratumoral pressure and immunosuppression addresses critical challenges in oncology drug delivery. The introduction of new PEDD devices and expansion into thyroid disease treatment indicates a strategy to broaden its addressable market and leverage existing technology. The reliance on CMS reimbursement codes highlights the importance of regulatory and healthcare policy in its commercial success, a common factor for medical device companies. The pursuit of a pharmaceutical partner for nelitolimod's clinical development aligns with typical biotech strategies for de-risking and funding late-stage trials.

Comparison to Industry Standards

• TriSalus's revenue growth of 47.5% for the six months ended June 30, 2025, is robust for a medical technology company, especially when compared to the average growth rates of established medical device companies, which often range from single to low double digits. This indicates strong market adoption for its TriNav system.
• The gross margin of 83.8% remains high, comparable to leading medical device companies that benefit from proprietary technology and high-value products. For instance, companies like Intuitive Surgical (robotics) or Medtronic (certain high-margin devices) can achieve gross margins in the 70-85% range, suggesting TriSalus's pricing power and cost structure for TriNav are competitive.
• The continued net losses and accumulated deficit of $298.2 million are typical for early-stage medical technology and biotech companies heavily investing in R&D and commercialization, particularly those with drug candidates like nelitolimod in clinical trials. This is common for companies like smaller biotechs developing novel therapies, which often operate at a loss for many years before potential profitability.
• The substantial doubt about going concern is a significant concern, but not entirely uncommon for companies in the pre-profitability phase of medical device or drug development, especially those reliant on external financing for clinical trials and market expansion. The recent capital raises (private placement and debt draw) are crucial for addressing this, but the underlying operational cash burn needs to be monitored.
• The material weaknesses in internal controls, particularly concerning complex accounting for significant transactions and IT security, are below industry best practices. Larger, more mature companies in the sector typically have robust internal control frameworks to ensure accurate financial reporting and compliance. Remediation efforts are critical to align with industry standards and investor expectations.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings.
• Not aware of any pending or threatened legal proceedings against the company that could have a material adverse effect on business, operating results, cash flows, or financial position.

Related Party Transactions

• The Standby Equity Purchase Agreement (SEPA) is with YA II PN, Ltd. ('Yorkville'), a fund managed by Yorkville Advisors Global, LP.
• The Credit Agreement is with OrbiMed Royalty & Credit Opportunities IV, LP ('OrbiMed'), a healthcare investment firm, and certain of its affiliates.

Stakeholder Impact

• **Shareholders**: Potential dilution from future equity raises to address going concern. Conversion of preferred stock simplifies capital structure. Share price volatility due to financial performance and going concern risk.
• **Employees**: Potential for hiring freezes or workforce reductions if additional capital is not secured. Stock-based compensation is a significant component of compensation.
• **Customers**: Continued availability of TriNav products and potential new applications (e.g., thyroid disease) could benefit patients and healthcare providers.
• **Creditors (OrbiMed)**: Debt obligations are subject to revenue targets and potential acceleration clauses. The company is in compliance with revenue base requirements as of June 30, 2025.
• **Regulatory Authorities (CMS, FDA)**: Ongoing efforts to secure and maintain reimbursement codes for TriNav and pursue FDA approval for nelitolimod are critical for market access and future revenue.

Next Steps

• Seek a pharmaceutical partner for future clinical development of nelitolimod, particularly after PERIO-03 Phase I data becomes available in 2025.
• Continue efforts to remediate identified material weaknesses in internal control over financial reporting, including hiring additional trained resources and improving processes.
• Evaluate the impact of the One Big Beautiful Bill Act on financial statements.
• Monitor and work towards achieving the $50.0 million Product Revenue Base to access the remaining $15.0 million under the OrbiMed Credit Agreement.
• Continue commercialization efforts for TriNav, including the newly launched TriNav FLX, and expand market adoption for the PEDD infusion systems.
• Enroll 100 patients across ten leading academic sites for the PROTECT registry study for thyroid disease.

Key Dates

Recommendation

While TriSalus demonstrates impressive revenue growth and has successfully raised capital to improve its immediate liquidity, the persistent net losses, substantial accumulated deficit, and explicit 'going concern' warning present significant fundamental risks. The identified material weaknesses in internal controls further add to the uncertainty. The company's innovative technology and market expansion efforts are positive, but the path to sustainable profitability and resolution of the going concern issue remains unclear. A 'hold' recommendation is appropriate for investors who are already exposed and believe in the long-term potential of the technology, but new investment is not advised given the high risk profile and lack of clear profitability.

Keywords

Medical Technology, Oncology, Solid Tumors, Drug Delivery, PEDD, TriNav, Nelitolimod, TLR9 Agonist, Clinical Trials, Reimbursement, HCPCS, Interventional Oncology, Liver Cancer, Pancreatic Cancer, Thyroid Disease, Biotechnology, Medical Devices